Clinicopathologic and Genomic Characterization of PD‐L1 Positive Urothelial Carcinomas

INTRODUCTION: Pembrolizumab was approved with an accompanying companion diagnostic (CDx) assay (PD‐L1 DAKO 22C3) for urothelial carcinoma (UC). In this study, we further characterize the clinicopathologic and genomic features of UC that are programmed death‐ligand 1 (PD‐L1) positive. MATERIALS AND M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Huang, Richard S.P., Haberberger, James, Harries, Lukas, Severson, Eric, Duncan, Daniel L., Ferguson, N. Lynn, Hemmerich, Amanda, Edgerly, Claire, Murugesan, Karthikeyan, Xiao, Jinpeng, McEwan, Deborah, Holmes, Oliver, Hiemenz, Matthew, Venstrom, Jeffrey, Elvin, Julia A., Creeden, James, Lin, Douglas I., Ross, Jeffrey S., Ramkissoon, Shakti H.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Cancer Diagnostics and Molecular Pathology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100538/
https://ncbi.nlm.nih.gov/pubmed/33687775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13753
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados